<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37069672</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>17</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Transforming growth factor beta 1 is associated with subclinical carotid atherosclerosis in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>64</StartPage><MedlinePgn>64</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">64</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-023-03046-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Transforming growth factor beta (TGF-&#x3b2;1) is a multifunctional cytokine that has anti-inflammatory and immunosuppressive effects. TGF-&#x3b2;1 has been linked to cardiovascular disease in the general population. The immunosuppressive effect of TGF-&#x3b2;1 is believed to be dysregulated in patients with systemic lupus erythematosus (SLE). In the present work, we aimed to study the relationship of serum levels of TGF-&#x3b2;1 with subclinical carotid atherosclerosis in patients with SLE.</AbstractText><AbstractText Label="METHODS">The study included 284 patients with SLE. Serum levels of TGF-&#x3b2;1 and subclinical carotid atherosclerosis (by carotid ultrasonography) were evaluated. In addition, the complete lipid profile and insulin resistance were analyzed. Multivariable linear and logistic regression analysis was performed to establish the relationship of TGF-&#x3b2;1 with carotid subclinical atherosclerosis adjusting for traditional cardiovascular risk factors that included lipid profile and insulin resistance.</AbstractText><AbstractText Label="RESULTS">Circulating TGF-&#x3b2;1 was positively and significantly associated with higher levels of LDL:HDL cholesterol ratio and atherogenic index. TGF-&#x3b2;1 was also associated with significantly lower levels of HDL cholesterol and apolipoprotein A1. Remarkably, TGF-&#x3b2;1 was associated with the presence of carotid plaque not only after adjustment for demographics (age, sex, body mass index, diabetes, hypertension, and aspirin use) but also after adjustment for relationships of TGF-&#x3b2;1 with lipid profile molecules, insulin resistance, and SLEDAI disease score (odds ratio 1.14 [95% confidence interval 1.003-1.30], p&#x2009;=&#x2009;0.045).</AbstractText><AbstractText Label="CONCLUSION">TGF-&#x3b2;1 serum levels are positively and independently associated with the presence of subclinical atherosclerosis disease in patients with SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf3;mez-Bernal</LastName><ForeName>Fuensanta</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quevedo-Abeledo</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Doctor Negr&#xed;n, Las Palmas de Gran Canaria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Gonz&#xe1;lez</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Cladera</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Rivero</LastName><ForeName>Agust&#xed;n F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Gonz&#xe1;lez</LastName><ForeName>Candelaria</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine, Hospital Universitario de Canarias, Tenerife, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of La Laguna (ULL), Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gonz&#xe1;lez-Gay</LastName><ForeName>Miguel &#xc1;</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Epidemiology, Genetics and Atherosclerosis Research Group On Systemic Inflammatory Diseases, Hospital Universitario Marqu&#xe9;s de Valdecilla, IDIVAL, Santander, Spain. miguelaggay@hotmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Universitario Marqu&#xe9;s de Valdecilla, Universidad de Cantabria, Santander, Spain. miguelaggay@hotmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. miguelaggay@hotmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, IIS-Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain. miguelaggay@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ferraz-Amaro</LastName><ForeName>Iv&#xe1;n</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain. iferrazamaro@hotmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of La Laguna (ULL), Tenerife, Spain. iferrazamaro@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508960">TGFB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002340" MajorTopicYN="Y">Carotid Artery Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053773" MajorTopicYN="Y">Transforming Growth Factor beta1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="N">Insulin Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="Y">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Transforming growth factor beta</Keyword></KeywordList><CoiStatement>Dr. Iv&#xe1;n Ferraz-Amaro would like to acknowledge that he has received grants/research supports from Abbott, MSD, Janssen, and Roche, as well as consultation fees from company-sponsored speakers bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, and MSD. Dr. M.A. Gonz&#xc1;lez-Gay has received grants/research supports from AbbVie, MSD, Janssen, and Roche, as well as consultation fees/participation from company-sponsored speakers bureaus tied to AbbVie, Pfizer, Roche, Sanofi, Lilly, Celgene, and MSD. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>0</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37069672</ArticleId><ArticleId IdType="pmc">PMC10108540</ArticleId><ArticleId IdType="doi">10.1186/s13075-023-03046-2</ArticleId><ArticleId IdType="pii">10.1186/s13075-023-03046-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li MO, Wan YY, Sanjabi S, Robertson AKL, Flavell RA. Transforming growth factor-&#x3b2; regulation of immune responses. Annu. Rev. Immunol. Annu Rev Immunol; 2006. p. 99&#x2013;146. Available from: https://pubmed.ncbi.nlm.nih.gov/16551245/. [Cited 8 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">16551245</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. Annu Rev Immunol; 2007;25:821&#x2013;52. Available from: https://pubmed.ncbi.nlm.nih.gov/17201677/. [Cited 8 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">17201677</ArticleId></ArticleIdList></Reference><Reference><Citation>Prud&#x2019;homme GJ. Pathobiology of transforming growth factor &#x3b2; in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Investig. Nature Publishing Group; 2007. p. 1077&#x2013;91. Available from: https://www.nature.com/articles/3700669. [Cited 8 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">17724448</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. Semin Arthritis Rheum; 2013;43:77&#x2013;95. Available from: https://pubmed.ncbi.nlm.nih.gov/23422269/. [Cited 23 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">23422269</ArticleId></ArticleIdList></Reference><Reference><Citation>Quevedo-Abeledo JC, R&#xfa;a-Figueroa &#xcd;, S&#xe1;nchez-P&#xe9;rez H, Tejera-Segura B, De Vera-Gonz&#xe1;lez A, Gonz&#xe1;lez-Delgado A, et al. Disease damage influences cardiovascular risk reclassification based on carotid ultrasound in patients with systemic lupus erythematosus. J Rheumatol. 2019;46:483&#x2013;491. doi: 10.3899/jrheum.180881.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.180881</ArticleId><ArticleId IdType="pubmed">30647175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Gonz&#xe1;lez C, Ferrer-Moure C, Quevedo-Abeledo JC, Gonz&#xe1;lez-Gay M&#xc1;, Ferraz-Amaro I. Apolipoprotein C3 and beta-cell dysfunction are linked in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2021; Available from: http://www.ncbi.nlm.nih.gov/pubmed/34936546. [Cited 23 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">34936546</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Gonz&#xe1;lez C, Ferrer-Moure C, Carlos Quevedo-Abeledo J, de Vera-Gonz&#xe1;lez A, Gonz&#xe1;lez-Delgado A, S&#xe1;nchez-Mart&#xed;n J, et al. Apolipoprotein C-III in patients with systemic lupus erythematosus. Arthritis Res Ther. BioMed Central Ltd; 2022;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088095</ArticleId><ArticleId IdType="pubmed">35538496</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-P&#xe9;rez H, Quevedo-Abeledo JC, De Armas-Rillo L, Rua - Figueroa &#xcd;, Tejera-Segura B, Armas-Gonz&#xe1;lez E. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. Rheumatol (United Kingdom) Oxford University Press. 2020;59(10):2847&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">32065639</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-P&#xe9;rez H, Quevedo-Abeledo JC, Tejera-Segura B, de Armas-Rillo L, R&#xfa;a-Figueroa I, Gonz&#xe1;lez-Gay MA, et al. Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Ther Adv Musculoskelet Dis. SAGE Publications Ltd; 2020;12:1759720X20975904. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33294038. [Cited 23 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7705780</ArticleId><ArticleId IdType="pubmed">33294038</ArticleId></ArticleIdList></Reference><Reference><Citation>Quevedo-Abeledo JC, Mart&#xed;n-Gonz&#xe1;lez C, Ferrer-Moure C, de Armas-Rillo L, Hernandez-Hernandez MV, Gonz&#xe1;lez-Gay M, et al. Key molecules of triglycerides pathway metabolism are disturbed in patients with systemic lupus erythematosus. Front Immunol.&#xa0;2022;13:827355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9124762</ArticleId><ArticleId IdType="pubmed">35615358</ArticleId></ArticleIdList></Reference><Reference><Citation>Quevedo-Abeledo JC, Hernandez-D&#xed;az M, S&#xe1;nchez-Perez H, Medina-Vega L, Gonz&#xe1;lez-Rivero AF, Almeida-Santiago C, et al. Amylin serum levels are upregulated in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2022;40:1378&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">34596033</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Dorta A, Quevedo-Abeledo JC, Rua-Figueroa &#xcd;, de Vera-Gonz&#xe1;lez AM, Gonz&#xe1;lez-Delgado A, Medina-Vega L, et al. Beta-cell function is disrupted in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:3826&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">33369681</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Gonz&#xe1;lez C, Ferrer-Moure C, Quevedo-Abeledo JC, Gonz&#xe1;lez-Gay M&#xc1;, Ferraz-Amaro I. Apolipoprotein C3 and beta-cell dysfunction are linked in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2021;40:2032&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">34936546</ArticleId></ArticleIdList></Reference><Reference><Citation>Batuman O, Go D, Clark LT, Smith ELP, Clements P, Feit A, et al. Relationship between cytokine levels and coronary artery disease in women. Heart Dis. Heart Dis.&#xa0;2001;3:80&#x2013;4. Available from: https://pubmed.ncbi.nlm.nih.gov/11975775/.</Citation><ArticleIdList><ArticleId IdType="pubmed">11975775</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG, Kumar S. The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis. Atherosclerosis; 2000;152:249&#x2013;56. Available from: https://pubmed.ncbi.nlm.nih.gov/10996361/. [Cited 23 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">10996361</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, et al. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. Nat Med; 1995;1:74&#x2013;9. Available from: https://pubmed.ncbi.nlm.nih.gov/7584958/. [Cited 23 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">7584958</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Dijke P, Arthur HM. Extracellular control of TGF&#x3b2; signalling in vascular development and disease. Nat. Rev. Mol. Cell Biol. Nat Rev Mol Cell Biol; 2007. p. 857&#x2013;69. Available from: https://pubmed.ncbi.nlm.nih.gov/17895899/. [Cited 23 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">17895899</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Gonz&#xe1;lez D de J, G&#xf3;mez-Martin D, Layseca-Espinosa E, Baranda L, Abud-Mendoza C, Alcocer-Varela J, et al. Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus. Clin Exp Immunol. Clin Exp Immunol; 2018 [cited 2022 Oct 9];191:288&#x2013;300. Available from: https://pubmed.ncbi.nlm.nih.gov/29058308/. [Cited 2022 Oct 9]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801498</ArticleId><ArticleId IdType="pubmed">29058308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol [Internet]. 1998 [cited 2022 Oct 12];160:2539&#x2013;45. Available from: https://pubmed.ncbi.nlm.nih.gov/9498800/</Citation><ArticleIdList><ArticleId IdType="pubmed">9498800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka K, Gray JD, Quismorio FP, Lee W, Horwitz DA. Cytokine-mediated down-regulation of B cell activity in SLE: effects of interleukin-2 and transforming growth factor-beta. Lupus. Lupus; 1999 [cited 2022 Oct 12];8:95&#x2013;102. Available from: https://pubmed.ncbi.nlm.nih.gov/10192502/. [Cited 12 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">10192502</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9324032. [Cited 30 May 2019]</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487&#x2013;95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15161807. [Cited 9 Mar 2019]</Citation><ArticleIdList><ArticleId IdType="pubmed">15161807</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowltz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol. 2002;29:288&#x2013;91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11838846. [Cited 10 Nov 2018]</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363&#x2013;9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8607884. [Cited 10 Nov 2018]</Citation><ArticleIdList><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol.;24:S-99&#x2013;104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17083771. [Cited 30 May 2019]</Citation><ArticleIdList><ArticleId IdType="pubmed">17083771</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz JD, Senegal J-L, Rivest C, Goulet J-R, Rothfield N. A simple severity of disease index for systemic lupus erythematosus. Lupus. 1993;2:119&#x2013;23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8330033. [Cited 30 May 2019]</Citation><ArticleIdList><ArticleId IdType="pubmed">8330033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejera-Segura B, Mac&#xed;a-D&#xed;az M, Machado JD, de Vera-Gonz&#xe1;lez A, Garc&#xed;a-Dopico JA, Olmos JM, et al. HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. Arthritis Res Ther. 2017;19:113. Available from: http://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1311-3. [Cited 10 Jun 2019]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5452399</ArticleId><ArticleId IdType="pubmed">28569219</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrales A, Gonz&#xe1;lez-Juanatey C, Peir&#xf3; ME, Blanco R, Llorca J, Gonz&#xe1;lez-Gay MA. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis. 2014;73:722&#x2013;7. Available from: http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2012-203101. [Cited 30 May 2019]</Citation><ArticleIdList><ArticleId IdType="pubmed">23505241</ArticleId></ArticleIdList></Reference><Reference><Citation>Touboul P-J, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004&#x2013;2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23:75&#x2013;80. Available from: https://www.karger.com/Article/FullText/97034. [Cited 30 May 2019]</Citation><ArticleIdList><ArticleId IdType="pubmed">17108679</ArticleId></ArticleIdList></Reference><Reference><Citation>Metawie SA, ElRefai RM, ElAdle SS, Shahin RMH. Transforming growth factor-&#x3b2;1 in systemic lupus erythematosus patients and its relation to organ damage and disease activity. Egypt Rheumatol Elsevier. 2015;37:S49&#x2013;54.</Citation></Reference><Reference><Citation>Rashad NM, El-Shabrawy RM, Said D, El-Shabrawy SM, Emad G. Serum levels of transforming growth factor beta-1 (TGF-&#x3b2;1) as an early no invasive marker for diagnosis of lupus nephritis in systemic lupus erythematosus patients. Egypt J Immuno. 2019;26:31&#x2013;42. Available from: https://pubmed.ncbi.nlm.nih.gov/31332994/. [Cited 11 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">31332994</ArticleId></ArticleIdList></Reference><Reference><Citation>Prud&#x2019;homme GJ. Pathobiology of transforming growth factor &#x3b2; in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Investig. Nature Publishing Group; 2007. p. 1077&#x2013;91. Available from: https://www.nature.com/articles/370066. [Cited 12 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">17724448</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Lei W, Chen W, Zhong J, Gao X, Li B, et al. Serum TGF-&#x3b2;1 and SMAD3 levels are closely associated with coronary artery disease. BMC Cardiovasc Disord. BioMed Central Ltd.; 2014;14:1&#x2013;7. Available from: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/1471-2261-14-18. [Cited 23 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3936998</ArticleId><ArticleId IdType="pubmed">24533640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE. Activation of transforming growth factor-&#x3b2;1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther. 2006;8. Available from: http://arthritis-research.com/content/8/3/R81Thisarticleisonlineat. [Cited 24 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1526639</ArticleId><ArticleId IdType="pubmed">16646981</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson IB, Horiguchi M, Zilberberg L, Dabovic B, Hadjiolova K, Rifkin DB. Latent TGF-&#x3b2;-binding proteins. Matrix Biol. NIH Public Access; 2015:44&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844006</ArticleId><ArticleId IdType="pubmed">25960419</ArticleId></ArticleIdList></Reference><Reference><Citation>Spence D. Measurement of intima-media thickness vs. carotid plaque: uses in patient care, genetic research and evaluation of new therapies. Int. J. Stroke. Int J Stroke; 2006. p. 216&#x2013;21. Available from: https://pubmed.ncbi.nlm.nih.gov/18706019/. [Cited 23 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">18706019</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon A, Megnien JL, Chironi G. The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. Lippincott Williams &amp; Wilkins; 2010. p. 182&#x2013;5. Available from: https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.109.196980. [Cited 23 Oct 2022]</Citation><ArticleIdList><ArticleId IdType="pubmed">19948842</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>